Third Harmonic hires Dinsmore as CSO
Plus: Matthew Shields to lead global operations at Teva, and updates from Compugen, Enhanc3D, Geneoscopy and Autism Speaks
Third Harmonic Bio Inc. (NASDAQ:THRD) named three executives to new positions as the company bounces back from a Phase Ib setback in 2022. The biotech hired Christopher Dinsmore as CSO and Dennis Dean as chief non-clinical development officer; it also promoted Jennifer Dittman to chief development operations officer from VP of regulatory affairs. Dinsmore was CSO of Kronos Bio Inc. (NASDAQ:KRON) and succeeds Adrian Ray, who became scientific adviser last November and departed in February. Dean was chief development officer of IFM Therapeutics Inc. Third Harmonic added that FDA cleared the company’s IND application for THB335 to treat mast cell-mediated diseases, with Phase I data for the KIT inhibitor expected in 1H25.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) hired Matthew Shields as EVP of Teva Global Operations, the company’s manufacturing and supply division, effective June 3. Shields was SVP for animal health manufacturing at Merck & Co. Inc. (NYSE:MRK) and succeeds Eric Drapé, who is leaving after 11 years with Teva...